Repligen Corp (RGEN) has been settling near the bottom of the trading range on low volume. It has formed a small head and shoulders pattern, but it seems to have relatively good support around...(read more
Repligen Corporation (RGEN) is a biopharmaceutical company which engages in the development and commercialization of therapies that deliver value to patients and clinicians in...(read more
Repligen Corporation (Nasdaq: RGEN) reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.
This study is a...(read more